Cover Image
市場調查報告書

類風濕性關節炎 (RA) 治療藥的全球市場 2017-2027年:生物製藥 (bDMARD)、合成抗風濕藥 (sDMARD)

Rheumatoid Arthritis (RA) Drugs Market 2017-2027: Trends, Progress & Revenue Forecasting - Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra & Biosimilars, Leading Companies

出版商 Visiongain Ltd 商品編碼 220557
出版日期 內容資訊 英文 183 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類風濕性關節炎 (RA) 治療藥的全球市場 2017-2027年:生物製藥 (bDMARD)、合成抗風濕藥 (sDMARD) Rheumatoid Arthritis (RA) Drugs Market 2017-2027: Trends, Progress & Revenue Forecasting - Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra & Biosimilars, Leading Companies
出版日期: 2017年11月03日 內容資訊: 英文 183 Pages
簡介

本報告提供全球類風濕性關節炎 (RA) 治療藥市場相關調查分析,各主要產品的收益預測,各地區趨勢,研究開發,市場競爭和機會等彙整資料,為您概述為以下內容。

第1章 調查概要

第2章 所謂類風濕性關節炎

  • 所謂類風濕性關節炎的原因
  • 疾病如何發展
  • 檢驗方法
  • RA能治療嗎
  • 臨床實驗所使用的評價標準
  • RA的治療方法
  • RA相關的合併症
  • RA的盛行率、發病率

第3章 全球類風濕性關節炎治療藥市場

  • 全球類風濕性關節炎市場
  • 全球RA治療藥市場:收益預測
  • 全球RA治療藥市場區隔:收益預測
  • RA用非生技藥品
    • NSAID:收益預測
    • 合成DMARD:收益預測
    • 其他:收益預測
  • RA用生技藥品:收益預測

第4章 RA市場上的主要治療藥

  • RA市場上主要治療藥
  • Humira
  • Enbrel
  • Remicade
  • Rituxan
  • Simponi
  • Orencia
  • Actemra
  • Cimzia
  • Celebrex
  • Xeljanz
  • Arcoxia

第5章 風濕的主要國家市場

  • 主要國家市場
  • 主要國家市場:收益、市場佔有率比較
  • 主要國家市場:各分類的收益預測
  • 美國:由於順利的經濟與大規模的患者人口在RA治療藥市場上具優勢
    • 美國的RA治療藥市場:收益預測
  • 維持日本:第二大市場
    • 日本的RA治療藥市場:收益預測
  • EU5個國家持有18%的市場佔有率
    • 德國的RA治療藥市場:收益預測
    • 法國RA治療藥市場:收益預測
    • 義大利RA治療藥市場:收益預測
    • 西班牙RA治療藥市場:收益預測
    • 英國RA治療藥市場:收益預測
  • 中國:經濟發展市場佔有率擴大
    • 中國的RA治療藥市場:收益預測
  • 印度:人口增加促進成長
    • 印度的RA治療藥市場:收益預測
  • 俄羅斯:由於混亂的經濟抑制擴大
    • 俄羅斯的RA治療藥市場:收益預測
  • 巴西:國內醫藥品製造的重視
    • 巴西的RA治療藥市場:收益預測

第6章 類風濕性關節炎的研發產品線

  • IL-6抑制劑TNF抑制劑的對手
  • JAK抑制劑:有前途的試劑類
  • BTK抑制劑
  • GM-CSF抑制劑

第7章 類風濕性關節炎治療藥市場上的主要企業

  • 主要企業的簡介
  • AbbVie:確保Humira的複數專利
  • Roche:第2名企業
  • Johnson & Johnson:對於Sirukumab的大期待
  • Amgen:Enbrel銷售受美國保護
  • Pfizer:活躍地開發生物相似藥
  • Merck & Co.: Remicade的銷售額減少
  • BMS:探索Orencia的適應擴大
  • UCB:Cimzia收益的依賴

第8章 類風濕性關節炎治療藥市場定性分析

  • 類風濕性關節炎市場優勢、弱點
  • 類風濕性關節炎市場面臨的機會、威脅
  • 類風濕性關節炎市場STEP分析

第9章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0256

Title:
RHEUMATOID ARTHRITIS (RA) DRUGS MARKET 2017-2027
Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors.

Report Details

  • Do you need definitive Rheumatoid Arthritis market data?
  • Succinct Rheumatoid Arthritis market analysis?
  • Technological insight?
  • Clear competitor analysis?
  • Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The introduction of new biologic drugs in Rheumatoid Arthritis, has led Visiongain to publish this timely report. The Rheumatoid Arthritis Drugs market is expected to flourish in the next few years because of rise to prominence of biosimilars that provides a way of reducing the cost of treatment for patients. In addition, the arrival of new JAK inhibitors and BTK inhibitors could provide patients with oral treatments rather than taking their medications intravenously. The expected increases in efficacy are expected to feed through in the latter part of the decade driving growth to new heights. If you want to be part of this growing industry, then read on to discover how you can maximise your investment potential.

Report highlights

135 quantitative tables, charts, and graphs across 183 pages

Analysis of key players in Rheumatoid Arthritis Market

  • AbbVie Pharmaceuticals
  • Roche Pharmaceuticals
  • Johnson & Johnson
  • Amgen
  • Pfizer
  • Merck and Co.
  • BMS
  • UCB

Global Rheumatoid Arthritis market outlook and analysis from 2017-2027

Global Rheumatoid Arthritis Drugs forecasts and analysis from 2017-2027

  • Major Biologics drugs forecast 2017-2027
  • Major non-biologics drugs forecast 2017-2027
  • Leading drugs forecast 2017-2027

Regional Rheumatoid Arthritis market forecasts from 2017-2027

  • US forecast 2017-2027,
  • Japan forecast 2017-2027
  • India forecast 2017-2027
  • Germany forecast 2017-2027
  • UK forecast 2017-2027
  • France forecast 2017-2027
  • Italy forecast 2017-2027
  • Spain forecast 2017-2027
  • Brazil forecast 2017-2027
  • Russia forecast 2017-2027
  • China forecast 2017-2027

Key questions answered

  • What does the future hold for the Pharmaceutical industry with regards to RA?
  • Where should you target your business strategy?
  • Which applications should you focus upon?
  • Which disruptive technologies should you invest in?
  • Which companies should you form strategic alliances with?
  • Which company is likely to success and why?
  • What business models should you adopt?
  • What industry trends should you be aware of?

Target audience

  • Leading Pharmaceutical companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Banks

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Rheumatoid Arthritis Overview
  • 1.2. Rheumatoid Arthritis Market Segmentation
  • 1.3. Why You Should Read this Report
  • 1.4. How this Report Delivers
  • 1.5. Main Questions Answered by this Report
  • 1.6. Who is this Report for?
  • 1.7. Research and Analysis Methods
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Some Associated Reports
  • 1.10. About Visiongain

2. What is Rheumatoid Arthritis?

  • 2.1. What Causes Rheumatoid Arthritis?
  • 2.2. How Does the Disease Develop?
  • 2.3. How Can It Be Monitored?
  • 2.4. Can RA Be Cured?
  • 2.5. Performance Criteria Used in Clinical Trials
    • 2.5.1. ACR Criteria For Drug Efficacy
    • 2.5.2. HAQ-DI Measures Daily Activities
    • 2.5.3. mSS Assesses Disease on X-Ray
    • 2.5.4. DAS28 For Disease Severity
  • 2.6. How is RA Treated?
    • 2.6.1. Biologic DMARDs Are the Dominant Source of Revenue
    • 2.6.2. Synthetic DMARDs are the Mainstay of Treatment
    • 2.6.3. Others
      • 2.6.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 2.6.3.2. Corticosteroids for Rapid Anti-Inflammatory Effect
      • 2.6.3.3. Analgesics for Rapid Pain Relief
  • 2.7. Comorbid Conditions Associated with RA
  • 2.8. Prevalence and Incidence Rates of Rheumatoid Arthritis

3. World Drug Market for Rheumatoid Arthritis 2017-2027

  • 3.1. The Global Rheumatoid Arthritis Market, 2016
  • 3.2. The Global RA Drugs Market: Revenue Forecast 2016-2027
  • 3.3. The Global RA Drugs Market Segments: Revenue Forecast 2016-2027
  • 3.4. Non-Biologics for RA
    • 3.4.1. NSAIDs: Revenue Forecast, 2016-2027
    • 3.4.2. Synthetic DMARDs: Revenue Forecast, 2016-2027
    • 3.4.3. Others: Revenue Forecast, 2016-2027
  • 3.5. Biologics for RA: Revenue Forecast 2016-2027

4. Leading Drugs in the RA Market 2017-2027

  • 4.1. The Main Drugs in the RA Market, 2016
  • 4.2. Humira: A Major Source of Revenue for AbbVie
    • 4.2.1. Adalimumab Biosimilars
    • 4.2.2. Humira: Revenue Forecast 2016-2027
  • 4.3. Enbrel: Amgen's Revenue Protected Until 2028
    • 4.3.1. Etanercept Biosimilars
    • 4.3.2. Enbrel: Revenue Forecast 2016-2027
  • 4.4. Remicade: Facing Significant Competition from Biosimilars
    • 4.4.1. Infliximab Biosimilars
    • 4.4.2. Remicade: Revenue Forecast 2016-2027
  • 4.5. Rituxan: Facing Declining Market Share
    • 4.5.1. Rituximab Biosimilars
    • 4.5.2. Rituxan: Revenue Forecast 2016-2027
  • 4.6. Simponi: Market Share Remaining Stable
    • 4.6.1. Simponi: Revenue Forecast 2016-2027
  • 4.7. Orencia: Additional Indications Being Explored
    • 4.7.1. Abatacept Biosimilars
    • 4.7.2. Orencia: Revenue Forecast 2016-2027
  • 4.8. Actemra: First IL-6R Inhibitor Approved for RA
    • 4.8.1. Tocilizumab Biosimilars
    • 4.8.2. Actemra: Revenue Forecast 2016-2027
  • 4.9. Cimzia: Reliable Source of Income for UCB
    • 4.9.1. Certolizumab Biosimilars
    • 4.9.2. Cimzia: Revenue Forecast 2016-2027
  • 4.10. Celebrex: Facing Generic Competition
    • 4.10.1. Celebrex: Revenue Forecast 2016-2027
  • 4.11. Xeljanz: Good Opportunity for Revenue Growth
    • 4.11.1. Xeljanz: Revenue Forecast 2016-2027
  • 4.12. Arcoxia: Sales Revenue Already Declining
    • 4.12.1. Arcoxia: Revenue Forecast 2016-2027

5. Leading National Markets for Rheumatoid Arthritis 2016-2027

  • 5.1. The Leading National Markets in 2016
  • 5.2. The Leading National Markets: Comparison of Revenues and Market Shares to 2027
  • 5.3. The Leading National Markets: Grouped Revenue Forecasts 2017-2027
  • 5.4. The US: Prosperous Economy and Large Patient Population Enables it to dominate the RA Drugs Market
    • 5.4.1. The US RA Drug Market: Revenue Forecast 2017-2027
  • 5.5. Japan: Remains the Second Largest National Market
    • 5.5.1. The RA Drug Market in Japan: Revenue Forecast 2017-2027
  • 5.6. The EU5 Have 18% Market Share
    • 5.6.1. The RA Drug Market in Germany: Revenue Forecast 2017-2027
    • 5.6.2. The RA Drug Market in France: Revenue Forecast 2017-2027
    • 5.6.3. The RA Drug Market in Italy: Revenue Forecast 2017-2027
    • 5.6.4. The RA Drug Market in Spain: Revenue Forecast 2017-2027
    • 5.6.5. The RA Drug Market in the UK: Revenue Forecast 2016-2026
  • 5.7. China: Expanding Economy with Increasing Market Share
    • 5.7.1. The RA Drug Market in China: Revenue Forecast 2017-2027
  • 5.8. India: Expanding Population Driving Growth
    • 5.8.1. The RA Drug Market in India: Revenue Forecast 2017-2027
  • 5.9. Russia: Expansion Held Back by Troubled Economy
    • 5.9.1. The RA Drug Market in Russia: Revenue Forecast 2017-2027
  • 5.10. Brazil: Focus on Domestic Drug Manufacturing
    • 5.10.1. The RA Drug Market in Brazil: Revenue Forecast 2017-2027

6. Rheumatoid Arthritis R&D Pipeline 2016

  • 6.1. IL-6. Inhibitors Could Rival TNF-Inhibitors
    • 6.1.1. Sarilumab: Already Filed With FDA
    • 6.1.2. Sirukumab: Expected to File in Q3, 2016
    • 6.1.3. Olokizumab: Promising Phase 2 Data
    • 6.1.4. Clazakizumab: Alder Now Collaborating with Vitaeris
  • 6.2. JAK Inhibitors: A Promising Class of Agents
    • 6.2.1. Baricitinib: Potential Competitor to Xeljanz
    • 6.2.2. Peficitinib: Selective JAK-3 Inhibitor From Astellas
    • 6.2.3. ABT-494: Selective JAK-1 Inhibitor From AbbVie
    • 6.2.4. Filgotinib: Following AbbVie's Withdrawal, Galapagos Now Working with Gilead
  • 6.3. BTK Inhibitors
    • 6.3.1. BMS-986142: Well Tolerated in Phase 1
    • 6.3.2. HM71224: Collaboration with Eli Lilly
  • 6.4. GM-CSF Inhibitor
    • 6.4.1. GSK 3196165: Potential Role in Early Disease

7. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2016

  • 7.1. Introduction to the Leading Companies
  • 7.2. AbbVie: Secured Multiple Patents for Humira
  • 7.3. Roche: Second-Leading Company
  • 7.4. Johnson & Johnson: High Hopes for Sirukumab
  • 7.5. Amgen: Enbrel Sales Protected in the US
  • 7.6. Pfizer: Actively Developing Biosimilars
  • 7.7. Merck & Co.: Remicade Sales in Decline
  • 7.8. BMS: Exploring Additional Indications for Orencia
  • 7.9. UCB: Reliant on Cimzia Revenue

8. Qualitative Analysis of the Rheumatoid Arthritis Drugs Market 2017-2027

  • 8.1. Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017
    • 8.1.1. Number of Elderly Patients Expected to Rise
    • 8.1.2. Biologics Already Recognised as a Valuable Part of Treatment
    • 8.1.3. Biologics Used in RA Often Have Multiple Indications
    • 8.1.4. Some Patients Have an Inadequate Treatment Response
    • 8.1.5. Efficacy of Drugs Can Diminish Over Time
  • 8.2. Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2017-2027
    • 8.2.1. Need for Effective Drugs With Better Safety Profiles
    • 8.2.2. Need for Less Invasive Routes of Administration
    • 8.2.3. High Number of Products Will Saturate Market
    • 8.2.4. Competition from Biosimilars Will Increase
  • 8.3. Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2017-2027
    • 8.3.1. Social Factors Influencing the Rheumatoid Arthritis Market
    • 8.3.2. Technological Factors Influencing the Rheumatoid Arthritis Market
    • 8.3.3. Economic Factors Influencing the Rheumatoid Arthritis Market
    • 8.3.4. Political Factors Influencing the Rheumatoid Arthritis Market
      • 8.3.4.1. Government Pressure to Control Costs
      • 8.3.4.2. Inter-country Variability in Biosimilar Approval Process

9. Conclusions

  • 9.1. Global Market for RA Drugs Will Contract After 2018
  • 9.2. Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By 10%
  • 9.3. Enbrel Will Overtake Humira as the Leading Drug
  • 9.4. US Will Remain the Dominant Market
  • 9.5. Trends in the RA Drugs Market
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 1.1: Main Segments and Sub-Segments of the Rheumatoid Arthritis Market, 2016
  • Figure 3.1: The Total RA Drugs Market: Market Share (%) by Indication, 2016
  • Figure 3.2: The RA Drugs Market: Market Share (%) by Submarket, 2016
  • Figure 3.3: The Drugs Market for RA: Revenue ($m) Forecast, 2017-2027
  • Figure 3.4: The RA Drugs Market Segments: Revenue* ($m) Forecast, 2016-2027
  • Figure 3.5: The RA Drugs Market: Market Share (%) by Segment, 2021
  • Figure 3.6: The RA Drugs Market: Market Share (%) by Segment, 2027
  • Figure 3.7: Non-Biologics for RA: Revenue* ($m) Forecasts by Segment, 2016-2027
  • Figure 3.8: Non-Biologics for RA: Market Share (%), 2016
  • Figure 3.9: Non-Biologics for RA: Market Share (%), 2021
  • Figure 3.10: Non-Biologics for RA: Market Share (%), 2027
  • Figure 3.11: NSAIDs: Revenue ($m) Forecast, 2016-2027
  • Figure 3.12: sDMARDs: Revenue ($m) Forecast, 2016-2027
  • Figure 3.13: Others: Revenue ($m) Forecast, 2016-2027
  • Figure 3.14: Biologics for RA: Revenue ($m) Forecast, 2016-2027
  • Figure 4.1: The Main Drugs in the RA Market: Market Shares (%), 2016.
  • Figure 4.2: Humira: Revenue ($m) Forecast, 2016-2027
  • Figure 4.3: Enbrel: Revenue ($m) Forecast, 2016-2027
  • Figure 4.4: Remicade: Revenue ($m) Forecast, 2016-2027
  • Figure 4.5: Rituxan: Revenue ($m) Forecast, 2016-2027
  • Figure 4.6: Simponi: Revenue ($m) Forecast, 2016-2027
  • Figure 4.7: Orencia: Revenue ($m) Forecast, 2016-2027
  • Figure 4.8: Actemra: Revenue ($m) Forecast, 2016-2027
  • Figure 4.9: Cimzia: Revenue ($m) Forecast, 2016-2027
  • Figure 4.10: Celebrex: Revenue ($m) Forecast, 2016-2027
  • Figure 4.11: Xeljanz: Revenue ($m) Forecast, 2016-2027
  • Figure 4.12: Arcoxia: Revenue ($m) Forecast, 2016-2027
  • Figure 5.1: RA: Market Share (%) by Country, 2016
  • Figure 5.2: RA: Market Share (%) by Country, 2027
  • Figure 5.3: The US RA Drug Market: World Market Share (%), 2016
  • Figure 5.4: The US RA Drug Market: Revenue ($m) Forecast, 2016-2027
  • Figure 5.5: The RA Drug Market in Japan: World Market Share (%), 2016
  • Figure 5.6: The RA Drug Market in Japan: Revenue ($m) Forecast, 2016-2027
  • Figure 5.7: The EU5 RA Drug Markets: World Market Share (%), 2016
  • Figure 5.8: The EU5 RA Drug Markets: Revenue ($m) Forecast 2016-2027
  • Figure 5.9: The RA Drug Market in Germany: World Market Share (%), 2016
  • Figure 5.10: The RA Drug Market in Germany: Revenue ($m) Forecast 2016-2027
  • Figure 5.11: The RA Drug Market in France: World Market Share (%), 2016
  • Figure 5.12: The RA Drug Market in France: Revenue ($m) Forecast, 2016-2027
  • Figure 5.13: The RA Drug Market in Italy: World Market Share (%), 2016
  • Figure 5.14: The RA Drug Market in Italy: Revenue ($m) Forecast, 2016-2027
  • Figure 5.15: The RA Drug Market in Spain: World Market Share (%), 2016
  • Figure 5.16: The RA Drug Market in Spain: Revenue ($m) Forecast, 2016-2027
  • Figure 5.17: The RA Drug Market in the UK: World Market Share (%), 2016
  • Figure 5.18: The RA Drug Market in the UK: Revenue ($m) Forecast, 2016-2027
  • Figure 5.19: The RA Drug Market in China: World Market Share (%), 2016
  • Figure 5.20: The RA Drug Market in China: Revenue ($m) Forecast, 2016-2027
  • Figure 5.21: The RA Drug Market in India: World Market Share (%), 2016
  • Figure 5.22: The RA Drug Market in India: Revenue ($m) Forecast, 2016-2027
  • Figure 5.23: The RA Drug Market in Russia: World Market Share (%), 2016
  • Figure 5.24: The RA Drug Market in Russia: Revenue ($m) Forecast, 2016-2027
  • Figure 5.25: The RA Drug Market in Brazil: World Market Share (%), 2016
  • Figure 5.26: The RA Drug Market in Brazil: Revenue ($m) Forecast, 2016-2027
  • Figure 7.1: Leading Companies in the RA Drug Market: Market Share (%), 2016
  • Figure 7.2: AbbVie: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.3: Roche: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.4: J&J: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.5: Amgen: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.6: Pfizer: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.7: Merck & Co: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.8: BMS: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 7.9: UCB: Breakdown of Revenue (%) by RA Drug, 2016
  • Figure 9.1: RA Drugs Market: Comparison of Revenue ($m) Forecasts for Total Market* and Market for RA Indication^, 2016-2027
  • Figure 9.2: RA Drugs Market: Comparison of Revenue* ($m) Forecasts for Biologic and Non-Biologic Segments, 2016-2027
  • Figure 9.3: The Leading Drugs in the RA Market: Revenue* ($m) Forecasts, 2016, 2022, 2027
  • Figure 9.4: The Leading National Markets for RA Drugs: Revenue* ($m) Forecasts, 2016, 2022, 2027

List of Tables

  • Table 1.1: Sample
  • Table 2.1: Biologic Agents and Mechanism of Action
  • Table 2.2: Comorbidities Associated with RA in Different Organs
  • Table 2.3: Prevalence rate of RA in Different Countries
  • Table 3.1: The RA Drugs Market by Submarket, 2016
  • Table 3.2: The Drugs Market for RA: Revenue* ($m) Forecast, 2016-2027
  • Table 3.3: The RA Drugs Market Segments Forecast: Revenue* ($m), AGR (%) & CAGR (%) 2016-2027
  • Table 3.4: Non-Biologics for RA: Revenue* ($m) Forecasts by Segment, 2016-2027
  • Table 3.5: NSAIDs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 3.6: sDMARDs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 3.7: Other Drugs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 3.8: Biologics for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.1: The Main Drugs in the RA Market: Revenue* ($m) and Market Share (%), 2016
  • Table 4.2: The Main Drugs in the RA Market Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3: Humira: Key Facts
  • Table 4.4: Adalimumab Biosimilars: Current Status, 2016
  • Table 4.5: Humira Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6: Humira: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.7: Enbrel: Key Facts
  • Table 4.8: Etanercept Biosimilars : Current Status, 2016
  • Table 4.9: Enbrel: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.10: Remicade: Key Facts
  • Table 4.11: Infliximab Biosimilars: Current Status, 2016
  • Table 4.12: Remicade: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.13: Rituxan: Key Facts
  • Table 4.14: Rituximab Biosimilars: Current Status, 2016
  • Table 4.15: Rituxan: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.16: Simponi: Key Facts
  • Table 4.17: Simponi: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.18: Orencia: Key Facts
  • Table 4.19: Orencia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.20: Actemra: Key Facts
  • Table 4.21: Actemra: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.22: Cimzia: Key Facts
  • Table 4.23: Cimzia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.24: Celebrex: Key Facts
  • Table 4.25: Celebrex: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.26: Xeljanz: Key Facts
  • Table 4.27: Xeljanz: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 4.28: Arcoxia: Key Facts
  • Table 4.29: Arcoxia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.1: The Leading National Markets for RA: Revenue* ($m) and Market Share (%), 2016
  • Table 5.2: RA Drugs: Market Share (%) by Country, 2016 and 2027
  • Table 5.3: RA Drugs: Revenue ($m) Forecast by Country, 2016-2027
  • Table 5.4: The US RA Drug Market: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.5: The RA Drug Market in Japan: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.6: The EU5 RA Drug Markets: Revenue ($m) Forecast, 2016-2027
  • Table 5.7: The RA Drug Market in Germany: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.8: The RA Drug Market in France: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.9: The RA Drug Market in Italy: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.10: The RA Drug Market in Spain: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.11: The RA Drug Market in the UK: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.12: The RA Drug Market in China: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.13: The RA Drug Market in India: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.14: The RA Drug Market in Russia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 5.15: The RA Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecast, 2016-2027
  • Table 6.1: Pipeline R&D Products, 2016
  • Table 7.1: Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2016
  • Table 7.2: AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.3: Roche: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.4: J&J: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.5: Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.6: Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.7: Merck & Co: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.8: BMS: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 7.9: UCB: Breakdown of Revenue ($m,%) by RA Drug, 2016
  • Table 8.1: Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017
  • Table 8.2: Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2017-2027
  • Table 8.3: Social, Technological, Economic and Political Factors Influencing the RA Market, 2016-2026
  • Table 9.1: Drivers and Restraints of the RA Drugs Market, 2017-2027

Companies Listed

  • Abbvie
  • Ablynx
  • Abott Laboratories
  • Alder
  • Amgen
  • Astellas
  • Baxalta
  • Biocad
  • Biocon
  • Biogen
  • Bioxpress Therapeutics
  • BMS
  • Boehringer Ingelheim
  • Can-Fite
  • Celtrion
  • Chugai Pharmaceutical Co Ltd.
  • Cipla
  • Coherus Biosciences Inc
  • Covagen AG
  • Daiichi Sankyo
  • Dr Reddy's Laboratories
  • Eli Lilly
  • Epirus
  • Fujifilm Kyowa Kirin
  • Galapagos
  • Genentech
  • Gilead Sciences Inc
  • GSK
  • Hanmi
  • Hanwha Chemical
  • Hetero Group
  • Hospira
  • IMS Health
  • Incyte
  • Intas
  • Janseen Biologics
  • Johnson and Johnson
  • LG Life Sciences
  • Merk
  • Mitshubisi
  • Momenta
  • MorphoSys
  • Mycenax Biotech
  • Mylan
  • Nichi-lko
  • Novartis
  • Oncobiologics
  • Pfenex
  • Pfizer
  • Protalix Biotherapeutics
  • Regeneron
  • Roche
  • Samsung Bioepis
  • Sanofi
  • Shanghai Celgen
  • Shanghai CP Goujian Pharmaceutical Co
  • Sharp & Dhome
  • Simcere Pharmaceuticals
  • Sun Pharma
  • Takeda
  • Tanabe Pharma
  • Torrent Pharmaceuticals
  • TSH Biopharm
  • UCB
  • Van der Heijde
  • Vitaeris
  • Zydus Cadila

List of Organizations

  • European Medicines Agency
  • Food Drug and Administration
  • Ministry of Health, Labor and Welfare
  • World Health Organization
Back to Top